Effective Tacrolimus Treatment for Patients with Non-Severe Aplastic Anemia That is Refractory/Intolerant to Cyclosporine A: A Retrospective Study.
cyclosporine A
non-severe aplastic anemia
tacrolimus
Journal
Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
08
2020
accepted:
10
11
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
22
9
2021
Statut:
epublish
Résumé
For symptomatic non-severe aplastic anemia (NSAA) patients who cannot afford anti-thymocyte globulin (ATG) or allogeneic hematopoietic stem cell transplantation (HSCT), tacrolimus (FK) may be an option if these patients do not respond or become tolerant to cyclosporine A (CsA). We enrolled 101 NSAA patients who were refractory or intolerant to CsA with no chance of HSCT or ATG treatment and treated these patients with tacrolimus for at least 6 months, with follow-up for at least one year. The overall response rate (ORR) was 38.6% (complete response: 9.9%; partial response: 28.7%), and the median time to optimal response was 6 (3～10) months. Thirty-two (31.7%) cases had elevated creatinine levels. Eight (7.9%) cases had elevations in AST/ALT. A total of 25.6% (10/39) of patients relapsed at the end of follow-up. Age ( Our data suggest that tacrolimus is a salvage treatment for patients with NSAA that is refractory or intolerant to CsA.
Sections du résumé
BACKGROUND
BACKGROUND
For symptomatic non-severe aplastic anemia (NSAA) patients who cannot afford anti-thymocyte globulin (ATG) or allogeneic hematopoietic stem cell transplantation (HSCT), tacrolimus (FK) may be an option if these patients do not respond or become tolerant to cyclosporine A (CsA).
METHODS
METHODS
We enrolled 101 NSAA patients who were refractory or intolerant to CsA with no chance of HSCT or ATG treatment and treated these patients with tacrolimus for at least 6 months, with follow-up for at least one year.
RESULTS
RESULTS
The overall response rate (ORR) was 38.6% (complete response: 9.9%; partial response: 28.7%), and the median time to optimal response was 6 (3～10) months. Thirty-two (31.7%) cases had elevated creatinine levels. Eight (7.9%) cases had elevations in AST/ALT. A total of 25.6% (10/39) of patients relapsed at the end of follow-up. Age (
CONCLUSION
CONCLUSIONS
Our data suggest that tacrolimus is a salvage treatment for patients with NSAA that is refractory or intolerant to CsA.
Identifiants
pubmed: 33408460
doi: 10.2147/DDDT.S275975
pii: 275975
pmc: PMC7779311
doi:
Substances chimiques
Immunosuppressive Agents
0
Cyclosporine
83HN0GTJ6D
Tacrolimus
WM0HAQ4WNM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5711-5719Informations de copyright
© 2020 Du et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest for this work.
Références
Blood. 2007 Sep 1;110(5):1603-6
pubmed: 17463169
Ann Hematol. 2019 Aug;98(8):2009-2011
pubmed: 30891613
Blood. 1999 Apr 1;93(7):2191-5
pubmed: 10090926
Ann Hematol. 2019 Jun;98(6):1341-1350
pubmed: 30915499
Eur J Haematol. 2019 Jul;103(1):18-25
pubmed: 30977158
PLoS One. 2016 Nov 3;11(11):e0160421
pubmed: 27812112
Haematologica. 1992 Jul-Aug;77(4):369-70
pubmed: 1385279
Blood Cells Mol Dis. 2014 Sep;53(3):157-60
pubmed: 24931461
Pediatr Hematol Oncol. 2019 May;36(4):198-210
pubmed: 31287345
Transplantation. 2012 Jul 27;94(2):123-31
pubmed: 22743548
N Engl J Med. 1982 Mar 25;306(12):712-8
pubmed: 7038485
Drugs. 2019 Aug;79(12):1305-1319
pubmed: 31292909
Haematologica. 2015 Nov;100(11):1426-33
pubmed: 26273061
Acta Haematol. 2019;142(3):162-170
pubmed: 31091521
Pediatr Blood Cancer. 2009 Apr;52(4):525-7
pubmed: 19058202
Expert Rev Hematol. 2019 Oct;12(10):809-819
pubmed: 31311355
Blood. 2016 Sep 1;128(9):1193-205
pubmed: 27281795
Semin Hematol. 2000 Jan;37(1):102-9
pubmed: 10676915
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2008 Oct;24(10):989-92
pubmed: 18845086
Haematologica. 2001 Jan;86(1):110
pubmed: 11146586
Am J Ther. 2016 May-Jun;23(3):e810-24
pubmed: 25299636
Biol Blood Marrow Transplant. 2009 Dec;15(12):1603-8
pubmed: 19896085
Zhonghua Yi Xue Za Zhi. 2013 May 28;93(20):1541-5
pubmed: 24028719
Pediatr Blood Cancer. 2009 May;52(5):626-30
pubmed: 19148946
Biol Blood Marrow Transplant. 2015 Oct;21(10):1776-82
pubmed: 26033280
Clin Biochem. 1991 Feb;24(1):3-7
pubmed: 1711939